A new report suggests that the prostate cancer screening test, prostate specific antigen (PSA) has minimal value when it comes to finding prostate cancer, especially in older men. The report, published in CA: A Cancer Journal for Clinicians shows that routine PSA blood tests result in overdiagnosis of prostate cancer, resulting in unnecessary treatments , psychosocial harm, and treatments that are not needed, related to insignificant prostate cancer tumors.
Though deaths from prostate cancer have declined since the 1980’s, study authors Otis W. Brawley, M.D. of the American Cancer Society and Donna Ankerst, Ph.D. and Ian M. Thompson, M.D. of the University of Texas Health Science Center at San Antonio, say the contribution of prostate cancer screening, using PSA blood tests, does not reduce the risk of suffering from prostate cancer.
The study authors also say in the future prostate cancer screening should improve to include better screening methods, assessment of prostate cancer risk factors and treatment of urinary symptoms with the drug finasteride, used to for men with enlarged prostate.
PSA tests reduce lifetime risk of dying from prostate cancer from three percent to just 2.4 percent. In a related editorial, Peter Boyle, Ph.D., D.Sc., of the International Prevention Research Institute, Lyon, France and report co-author Dr. Brawley say "the real impact and tragedy of prostate cancer screening is the doubling of the lifetime risk of a diagnosis of prostate cancer with little if any decrease in the risk of dying from this disease."
According to the American Cancer Society, “There can be different reasons for an elevated PSA level, including prostate cancer, benign prostate enlargement, inflammation, infection, age, and race”, all factors that make PSA test results confusing, leading to potential for unnecessary treatment and suffering when tests are elevated.
The authors conclude, "men should discuss the now quantifiable risks and benefits of having a PSA test with their physician and then share in making an informed decision”. They contend that prostate cancer screening tests are not meeting the standard of reducing health care costs, or risk of death and suffering from prostate cancer .
CA Cancer J Clin, July/Aug 2009 doi:10.3322/caac.20026
Resource: http://www.cancer.gov/cancertopics/factsheet/detection/PSA
Comments
How it is important to better health to test every year for a persistent infection and how a healthy diet contributes to the body ridding itself of this infection naturally. HPV only becomes cancer when you do not get it treated early. The perfect example of this sadly is Jane Goody. She even said herself that she put off going back to her doctors when they told her about the cancer because she was scared. If she would have received information that was positive at 16 when first diagnosed then, I believe, she would not have had the fear that stopped her from going back to her doctor.
Great article! Very informative!
I am a physician who is against PSA screening. (See related post on www.MDWhistleblower.blogspot.com.) Patients are not being adequately informed about the poor performance of PSA testing before the test is run. This is one of medicine's most slippery slopes.
Thank you Dr. Kirsch. It's important to do a little "whistle-blowing". Interestingly, I have previously been to your blog, and think it's great! Thanks again.
Got something to say?
Examiner.com is looking for writers, photographers, and videographers to join the fastest growing group of local insiders. If you are interested in growing your online rep apply to be an Examiner today!